Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin
Deal-happy Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a licensing pact with Japanese biotech Kyorin potentially worth hundreds of millions of dollars.
Deal-happy Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a licensing pact with Japanese biotech Kyorin potentially worth hundreds of millions of dollars.
